Skyrizi Dosage, forms & strengths
Complete a free online enrollment application to find out if you’re eligible to pay only $49 per month for your Skyrizi medication.
Get started todaySkyrizi (risankizumab-rzaa) is a prescription interleukin-23 inhibitor that is manufactured by AbbVie Inc. It is classified as a monoclonal antibody that works by suppressing all or part of your immune system.
Skyrizi is approved by the U.S. Food and Drug Administration (FDA) to treat adults with:
- moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.
- active psoriatic arthritis (PsA).
- moderately to severely active Crohn’s disease.
Skyrizi dosage forms and strengths
Skyrizi is available in several dosage forms with the following strengths:
- 150mg/ml single-dose prefilled pen
- 150mg/ml single-dose prefilled syringe
- 75mg/0.83ml single-dose prefilled syringe
- 360mg/2.4ml (150mg/ml) single-dose prefilled cartridge with On-Body Injector
- 600 mg/10mL (60 mg/mL) single-dose vial for intravenous (IV) infusion
Skyrizi dosage for adults
Plaque psoriasis and psoriatic arthritis are dosed:
- 150mg via subcutaneous injection at Week 0, Week 4, and then every 12 weeks thereafter.
- Patients with psoriatic arthritis can be Skyrizi alone or along with non-biologic disease-modifying antirheumatic drugs (DMARDs).
Patients being treated for Crohn’s Disease should have their liver enzymes and bilirubin levels before starting Skyrizi and then can be given the following:
- The recommended induction dosage for Skyrizi is 600mg via IV infusion over at least 1 hour at Week 0, Week 4, and Week 8. You will then start your maintenance dosage of 360mg via subcutaneous injection at Week 12, and every 8 weeks thereafter.
Skyrizi adult dosage chart
| Indication | Starting dosage | Standard dosage | Maximum dosage |
|---|---|---|---|
| Plaque psoriasis | 150mg via injection under the skin at Week 0, Week 4, and every 12 weeks thereafter. | 150mg via injection under the skin every 12 weeks. | 150mg via injection under the skin every 12 weeks. |
| Psoriatic arthritis | 150mg via injection under the skin at Week 0, Week 4, and every 12 weeks thereafter. | 150mg via injection under the skin every 12 weeks. | 150mg via injection under the skin every 12 weeks. |
| Crohn’s disease | Induction dose: 600mg via a 1-hour IV infusion at Week 0, Week 4, and Week 8. | Maintenance dose: 360mg via injection under your skin at Week 12 and every 8 weeks thereafter. | 360mg via injection under your skin every 8 weeks. |
The safety and effectiveness of Skyrizi have not been established in children 18 years of age and younger.
Skyrizi dosage restrictions
- There is no dosage adjustment necessary for patients with hepatic (liver) or renal (kidney) impairment.
How to take Skyrizi
- Read the Full Prescribing Information, Instructions for Use, and Medication Guide that come with Skyrizi.
- Use Skyrizi exactly as your healthcare provider tells you to. Do not change the dose or stop taking Skyrizi without discussing it with your healthcare provider.
- Your healthcare provider will show you how to use Skyrizi before you give your first dose.
- Take Skyrizi out of the refrigerator and let it warm up to room temperature before using it. Allow 30-90 minutes for the prefilled pen and 15-30 minutes for the prefilled syringe.
- Skyrizi can be injected under the skin of your stomach or the front of your thighs. Do not inject Skyrizi within 2 inches of your belly button.
- If you miss a dose of Skyrizi, inject a dose right away, then administer your next dose at your regularly scheduled time.
- If you’ve injected too much Skyrizi, call your doctor right away.
- Skyrizi is given as a subcutaneous injection (under the skin) using a prefilled pen or prefilled syringe
- Skyrizi is given as an injection under the skin using a prefilled pen or prefilled syringe for patients being treated for plaque psoriasis or psoriatic arthritis.
- Patients with Crohn’s disease will receive their initial doses of Skyrizi as an intravenous (IV) infusion in a healthcare facility by your healthcare provider. After finishing your starter doses, you will be given Skyrizi as a subcutaneous injection using a prefilled cartridge with an on-body injector.
- It is not known how Skyrizi will affect your fetus. Talk with your healthcare provider to see if Skyrizi is right for you if you are pregnant or plan on becoming pregnant. There is a pregnancy exposure registry you can enroll in that monitors outcomes if you become pregnant while using Skyrizi. Call 1-877-302-2161 or visit http://glowpregnancyregistry.com for more information.
- It is not known if Skyrizi is found in breast milk or the effects it has on breastfed infants and milk production. Contact your healthcare provider for medical advice about the risks and benefits of breastfeeding while taking Skyrizi.
- Store Skyrizi in the refrigerator between 36°F to 46°F (2°C to 8°C) in the original carton. Do not freeze or shake Skyrizi.
Skyrizi dosage FAQs
What are some side effects of Skyrizi?
Some common adverse reactions to Skyrizi may include:
Some common side effects of Skyrizi may include:
- Upper respiratory infections
- Headache
- Fatigue
- Injection site reactions
- Tinea infections (fungal skin infections)
- Joint pain
- Abdominal pain
- Fever
Skyrizi can cause some serious side effects including:
- Serious hypersensitivity reactions, including anaphylaxis.
- Increased risk of infections, including serious infections such as tuberculosis and infections of the skin, bones, or blood. Notify your doctor if you have symptoms of an infection such as fever, sweats, cough, sore throat, shortness of breath, or pain while urinating.
- Liver injury while treating Crohn’s disease.
You can report any side effects you experience to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
What are some drug interactions with Skyrizi?
When Skyrizi is taken with other medicines, they may interact and change how those work. It may also increase the severity and frequency of certain side effects. Make sure your healthcare professional knows all the medications you take, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements. Some common drug interactions of Skyrizi include:
- Other medications that suppress your immune system
- Live vaccines
Are there any contraindications or precautions with Skyrizi?
You should not take this medication if you have had a serious allergic reaction to Skyrizi or any of its inactive ingredients.
Your doctor should evaluate you for tuberculosis (TB) before starting Skyrizi treatment. They may treat you for TB before you start taking Skyrizi if you have a history of TB or have active TB.
How long does Skyrizi stay in your system?
Skyrizi has a half-life of about 4 weeks in adults with plaque psoriasis and 3 weeks in those with Crohn’s disease so it can be in your bloodstream for 4 to 5 months.
Is it safe to use Skyrizi while pregnant or breastfeeding?
It is not known how Skyrizi affects the fetus if taken while pregnant or if it is found in breast milk. Talk with your doctor about the risks of taking Skyrizi if you are pregnant, plan on becoming pregnant, or are breastfeeding.
There is a pregnancy exposure registry that monitors outcomes if you become pregnant while taking Skyrizi. You can enroll by calling 1-877-302-2161 or visiting http://glowpregnancyregistry.com.
Will lab monitoring be done when taking Skyrizi?
Your doctor will do blood tests to check your liver before, during, and up to 12 weeks of treatment. Your treatment may be stopped if you develop liver problems.
